Additionally, Lee et al. found in HCC patients (n = 29) receiving atezolizumab combined with bevacizumab that patients with LAG3% > 9.08% in PD-1+ Tregs exhibited reduced OS [97]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.